48.68 USD
-0.18 (-0.37%)
48.68 USD
0 (0%)
Overall SNY gets a fundamental rating of 6 out of 10. We evaluated SNY against 191 industry peers in the Pharmaceuticals industry. SNY scores excellent on profitability, but there are some minor concerns on its financial health. SNY may be a bit undervalued, certainly considering the very reasonable score on growth SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
SNY had a positive operating cash flow in the past year.
SNY had positive earnings in each of the past 5 years.
SNY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 11.05%, SNY belongs to the best of the industry, outperforming 92.15% of the companies in the same industry.
With an excellent Return On Equity value of 19.73%, SNY belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
SNY has a Return On Invested Capital of 13.84%. This is amongst the best in the industry. SNY outperforms 93.19% of its industry peers.
SNY had an Average Return On Invested Capital over the past 3 years of 7.31%. This is significantly below the industry average of 12.85%.
The last Return On Invested Capital (13.84%) for SNY is above the 3 year average (7.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
SNY's Profit Margin of 20.35% is amongst the best of the industry. SNY outperforms 91.10% of its industry peers.
SNY's Profit Margin has improved in the last couple of years.
SNY has a Operating Margin of 23.59%. This is amongst the best in the industry. SNY outperforms 90.58% of its industry peers.
In the last couple of years the Operating Margin of SNY has grown nicely.
With a decent Gross Margin value of 71.70%, SNY is doing good in the industry, outperforming 78.53% of the companies in the same industry.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for SNY remains at a similar level compared to 1 year ago.
Compared to 5 years ago, SNY has about the same amount of shares outstanding.
Compared to 1 year ago, SNY has an improved debt to assets ratio.
2.2 Solvency
SNY has a debt to FCF ratio of 2.21. This is a good value and a sign of high solvency as SNY would need 2.21 years to pay back of all of its debts.
SNY has a Debt to FCF ratio of 2.21. This is amongst the best in the industry. SNY outperforms 93.19% of its industry peers.
SNY has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
SNY's Debt to Equity ratio of 0.21 is in line compared to the rest of the industry. SNY outperforms 43.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.88
WACC7.36%
2.3 Liquidity
A Current Ratio of 1.27 indicates that SNY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.27, SNY is doing worse than 77.49% of the companies in the same industry.
A Quick Ratio of 0.94 indicates that SNY may have some problems paying its short term obligations.
With a Quick ratio value of 0.94, SNY is not doing good in the industry: 79.06% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
SNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.35%.
The Earnings Per Share has been growing slightly by 5.10% on average over the past years.
SNY shows a small growth in Revenue. In the last year, the Revenue has grown by 2.56%.
SNY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.31% yearly.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
3.2 Future
SNY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.11% yearly.
Based on estimates for the next years, SNY will show a small growth in Revenue. The Revenue will grow by 4.55% on average per year.
EPS Next Y3.02%
EPS Next 2Y5.77%
EPS Next 3Y5.98%
EPS Next 5Y7.11%
Revenue Next Year0.64%
Revenue Next 2Y3.51%
Revenue Next 3Y4.42%
Revenue Next 5Y4.55%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.89, the valuation of SNY can be described as reasonable.
90.58% of the companies in the same industry are more expensive than SNY, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.54. SNY is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 9.63, which indicates a very decent valuation of SNY.
SNY's Price/Forward Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 87.96% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.78, SNY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.89 | ||
| Fwd PE | 9.63 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 97.38% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 90.58% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.01 | ||
| EV/EBITDA | 5.5 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNY does not grow enough to justify the current Price/Earnings ratio.
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.61
PEG (5Y)2.14
EPS Next 2Y5.77%
EPS Next 3Y5.98%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 4.69%, which is a nice return.
Compared to an average industry Dividend Yield of 0.71, SNY pays a better dividend. On top of this SNY pays more dividend than 97.38% of the companies listed in the same industry.
SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.96.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.69% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has paid a dividend for at least 10 years, which is a reliable track record.
SNY has decreased its dividend in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
SNY pays out 34.82% of its income as dividend. This is a sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y5.77%
EPS Next 3Y5.98%
48.68
-0.18 (-0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.31%
Inst Owner Change-5.34%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap118.24B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Analysts81.38
Price Target62.23 (27.83%)
Short Float %0.28%
Short Ratio1.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.69% |
Yearly Dividend2.23
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)-0.08%
PT rev (3m)-3.97%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)-4.38%
EPS NY rev (1m)0.24%
EPS NY rev (3m)-1.11%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-1.69%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)0.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.89 | ||
| Fwd PE | 9.63 | ||
| P/S | 1.48 | ||
| P/FCF | 10.01 | ||
| P/OCF | 8.86 | ||
| P/B | 1.44 | ||
| P/tB | 10.85 | ||
| EV/EBITDA | 5.5 |
EPS(TTM)4.47
EY9.18%
EPS(NY)5.05
Fwd EY10.38%
FCF(TTM)4.86
FCFY9.99%
OCF(TTM)5.5
OCFY11.29%
SpS32.79
BVpS33.81
TBVpS4.49
PEG (NY)3.61
PEG (5Y)2.14
Graham Number58.31
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.36%
ROIC/WACC1.88
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y3.02%
EPS Next 2Y5.77%
EPS Next 3Y5.98%
EPS Next 5Y7.11%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year0.64%
Revenue Next 2Y3.51%
Revenue Next 3Y4.42%
Revenue Next 5Y4.55%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year29.46%
EBIT Next 3Y13.42%
EBIT Next 5Y11.66%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%
SANOFI-ADR / SNY FAQ
What is the fundamental rating for SNY stock?
ChartMill assigns a fundamental rating of 6 / 10 to SNY.
What is the valuation status for SNY stock?
ChartMill assigns a valuation rating of 8 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.
How profitable is SANOFI-ADR (SNY) stock?
SANOFI-ADR (SNY) has a profitability rating of 8 / 10.
What is the valuation of SANOFI-ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 10.89 and the Price/Book (PB) ratio is 1.44.
Can you provide the financial health for SNY stock?
The financial health rating of SANOFI-ADR (SNY) is 4 / 10.